This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:diseases:ibs [02.17.2019] – [Irritable bowel syndrome (IBS)] sallieq | home:diseases:ibs [03.13.2019] – [Further researxh] sallieq | ||
---|---|---|---|
Line 3: | Line 3: | ||
====== Irritable bowel syndrome (IBS) ====== | ====== Irritable bowel syndrome (IBS) ====== | ||
- | <relatedarticle> [[home: | + | <relatedarticles> [[home: |
Line 47: | Line 47: | ||
Free versus total serum 25-hydroxyvitamin D in a murine model of colitis. | Free versus total serum 25-hydroxyvitamin D in a murine model of colitis. | ||
+ | |||
+ | ==== Further research ==== | ||
+ | |||
+ | Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. | ||
+ | |||
+ | In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity. | ||
+ | |||